Skip to content
2000
Volume 20, Issue 6
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

In recent years there has been increased interest in exploring the therapeutic efficacy of cannabis for the management of chronic pain among adult patients. However, the use of cannabis for chronic pain is still a matter of debate and uncertainty. This opinion paper carried out a short overview of the literature with the aim of evaluating data on efficacy and safety of cannabis-based medicines, to fill the existing gaps in understanding the role of cannabis in therapy and to identify the critical issues associated with their use. The analysis of existing literature has clearly highlighted the potential benefits of cannabis-based preparations for the management of chronic pain. However, several criticalities have been identified. These include the lack of standardization of preparations and the insufficient clinical evidence to establish cannabis as the therapy of choice for chronic pain. As a result, although the potential benefits of cannabis preparations for the management of chronic pain are clear, further research is needed to address existing limitations and establish a solid scientific basis, especially through real-world data collection.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855319068240915174752
2024-09-24
2025-10-23

  • From This Site

    /content/journals/cdth/10.2174/0115748855319068240915174752
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. YangS. ChangM.C. Chronic pain: Structural and functional changes in brain structures and associated negative affective states.Int. J. Mol. Sci.20192013313010.3390/ijms20133130 31248061
     [Google Scholar]
  2. KonstantinovV. ReznikA. ZangenehM. Foreign medical students in eastern europe: Knowledge, attitudes and beliefs about medical cannabis for pain management.Int. J. Environ. Res. Public Health2021184213710.3390/ijerph18042137 33671711
     [Google Scholar]
  3. Pantoja-RuizC. Restrepo-JimenezP. Castañeda-CardonaC. FerreirósA. RosselliD. Cannabis and pain: A scoping review.Braz. J. Anesthesiol.202272114215110.1016/j.bjane.2021.06.018
     [Google Scholar]
  4. AbaloE. Between facts and ambiguity: Discourses on medical cannabis in Swedish newspapers.Nord. Alkohol- Narkotikatidskrift202138434536010.1177/1455072521996997 35308110
     [Google Scholar]
  5. Millán-GuerreroR. Isais-MillánS. Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.Gac. Med. Mex.20191555471474
     [Google Scholar]
  6. BrubacherJ.R. ChanH. ErdelyiS. StaplesJ.A. AsbridgeM. MannR.E. Cannabis legalization and detection of tetrahydrocannabinol in injured drivers.N. Engl. J. Med.2022386214815610.1056/NEJMsa2109371 35020985
     [Google Scholar]
  7. VeceraL. GabrhelikT. PrasilP. StouracP. The role of cannabinoids in the treatment of cancer.Bratisl. Lek Listy20201211799510.4149/BLL_2020_012
     [Google Scholar]
  8. PetzkeF. TölleT. FitzcharlesM.A. HäuserW. Cannabis-based medicines and medical cannabis for chronic neuropathic pain.CNS Drugs2022361314410.1007/s40263‑021‑00879‑w 34802112
     [Google Scholar]
  9. PrattM. StevensA. ThukuM. Benefits and harms of medical cannabis: A scoping review of systematic reviews.Syst. Rev.20198132010.1186/s13643‑019‑1243‑x 31823819
     [Google Scholar]
  10. BenniciA. MannucciC. CalapaiF. Safety of medical cannabis in neuropathic chronic pain management.Molecules20212620625710.3390/molecules26206257 34684842
     [Google Scholar]
  11. KoenisM.M.G. DurnezJ. RodrigueA.L. Associations of cannabis use disorder with cognition, brain structure, and brain function in African Americans.Hum. Brain Mapp.20214261727174110.1002/hbm.25324 33340172
     [Google Scholar]
  12. van den HoogenN.J. HardingE.K. DavidsonC.E.D. TrangT. Cannabinoids in chronic pain: therapeutic potential through microglia modulation.Front. Neural Circuits202215816747
     [Google Scholar]
  13. McLaren-BladesA. LadhaK. GoelA. Perioperative pain and addiction interdisciplinary network (PAIN): Protocol for the perioperative management of cannabis and cannabinoid-based medicines using a modified Delphi process.BMJ Open2020107e03647210.1136/bmjopen‑2019‑036472 32690522
     [Google Scholar]
  14. SolmiM. De ToffolM. KimJ.Y. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.BMJ2023382e07234810.1136/bmj‑2022‑072348 37648266
     [Google Scholar]
  15. PertweeR.G. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin.Br. J. Pharmacol.2008153219921510.1038/sj.bjp.0707442 17828291
     [Google Scholar]
  16. KocisP.T. VranaK.E. Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions.Med. Cannabis Cannabinoids202031617310.1159/000507998 34676340
     [Google Scholar]
  17. HudsonR. RenardJ. NorrisC. RushlowW.J. LavioletteS.R. Cannabidiol counteracts the psychotropic side-effects of δ-9-tetrahydrocannabinol in the ventral hippocampus through bidirectional control of erk1–2 phosphorylation.J. Neurosci.201939448762877710.1523/JNEUROSCI.0708‑19.2019 31570536
     [Google Scholar]
  18. BreijyehZ. JubehB. BufoS.A. KaramanR. ScranoL. Cannabis: A toxin-producing plant with potential therapeutic uses.Toxins202113211710.3390/toxins13020117 33562446
     [Google Scholar]
  19. ChesneyE. OliverD. GreenA. Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials.Neuropsychopharmacology202045111799180610.1038/s41386‑020‑0667‑2 32268347
     [Google Scholar]
  20. AncionesC. Gil-NagelA. Adverse effects of cannabinoids.Epileptic Disord.202022S1293210.1684/epd.2019.1125 31941644
     [Google Scholar]
  21. SouzaJ.D.R. PachecoJ.C. RossiG.N. Adverse effects of oral cannabidiol: An updated systematic review of randomized controlled trials (2020–2022).Pharmaceutics20221412259810.3390/pharmaceutics14122598 36559092
     [Google Scholar]
  22. YauG.T.Y. TaiW. ArnoldJ.C. ChanH.K. KwokP.C.L. Cannabidiol for the treatment of brain disorders: Therapeutic potential and routes of administration.Pharm. Res.20234051087111410.1007/s11095‑023‑03469‑1 36635488
     [Google Scholar]
  23. HryhorowiczS. Kaczmarek-RyśM. ZielińskaA. ScottR.J. SłomskiR. PławskiA. Endocannabinoid system as a promising therapeutic target in inflammatory bowel disease – A systematic review.Front. Immunol.202112
     [Google Scholar]
  24. JacobsR.J. KaneM.N. CaballeroJ. Predictors of medical students’ perceptions about medical cannabis.Cureus2022144e2439010.7759/cureus.24390 35619867
     [Google Scholar]
  25. PaganoC. NavarraG. CoppolaL. AviliaG. BifulcoM. LaezzaC. Cannabinoids: Therapeutic use in clinical practice.Int. J. Mol. Sci.2022236334410.3390/ijms23063344 35328765
     [Google Scholar]
  26. SalamiS.A. MartinelliF. GiovinoA. BachariA. AradN. MantriN. It is our turn to get cannabis high: Put cannabinoids in food and health baskets.Molecules20202518403610.3390/molecules25184036 32899626
     [Google Scholar]
  27. BoehnkeK.F. YakasL. ScottJ.R. DeJonckheereM. LitinasE. SisleyS. A mixed methods analysis of cannabis use routines for chronic pain management.J. Cannabis Res.202241710.1186/s42238‑021‑00116‑7
     [Google Scholar]
  28. Cáceres GuidoP. RivaN. CalleG. Medicinal cannabis in Latin America: History, current state of regulation, and the role of the pharmacist in a new clinical experience with cannabidiol oil.J. Am. Pharm. Assoc.202060121221510.1016/j.japh.2019.09.012 31706799
     [Google Scholar]
  29. Rodríguez-VillaltaP.C. Cannabis without taboos: Analysis of the situation of cannabis consumption in Costa Rica.Revista Espiga2022214317119610.22458/re.v21i43.4250
     [Google Scholar]
  30. Chacón SerranoW. Méndez MuñozJ. Sánchez ChaverriG. Atlas of drug use in Costa Rica, 2015.2017Available from: https://iafa.go.cr/invest_psicoactivas/atlas-del-consumo-de-drogas-en-costa-rica-2015/
    [Google Scholar]
  31. Volio PachecoZ.R. Chan MoraC.I. Solís QuirósM.I. Niño GutiérrezA.K. Thompson ChacónR.H. Law on the production of cannabis and hemp for medicinal purposes.2019Available from: https://d1qqtien6gys07.cloudfront.net/wp-content/uploads/2021/04/21315.pdf
    [Google Scholar]
  32. Atencio DelgadoM. Law for the research, regulation and control of cannabis and hemp plants for medicinal, food and industrial use.2014Available from: https://www.asamblea.go.cr/sd/Documents/referencia%20y%20prestamos/BOLETINES/BOLETIN%2002/GENERAL/19256.%20%20Texto%20base.pdf
    [Google Scholar]
  33. LeinenZ.J. MohanR. PremadasaL.S. AcharyaA. MohanM. ByrareddyS.N. Therapeutic potential of cannabis: A comprehensive review of current and future applications.Biomedicines20231110263010.3390/biomedicines11102630 37893004
     [Google Scholar]
  34. JeffersA.M. GlantzS. ByersA. KeyhaniS. Sociodemographic characteristics associated with and prevalence and frequency of cannabis use among adults in the US.JAMA Netw. Open2021411e213657110.1001/jamanetworkopen.2021.36571 34846523
     [Google Scholar]
  35. ZürcherK. DupontC. WeberP. Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland.Eur. J. Pediatr.2022181133534710.1007/s00431‑021‑04202‑z 34309706
     [Google Scholar]
  36. Legislative review of the cannabis act: What we heard report.2023Available from: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/cannabis-act-legislative-review/expert-panel/legislative-review-cannabis-act-report.html
  37. MohiuddinM.M. MizubutiG.B. HaroutounianS. Adherence to consolidated standards of reporting trials (CONSORT) guidelines for reporting safety outcomes in trials of medical cannabis and cannabis-based medicines for chronic noncancer pain.Clin. J. Pain202036430231910.1097/AJP.0000000000000807 31977375
     [Google Scholar]
  38. KaufmannC. KimA. MiyoshiM. HanB. Patterns of medical cannabis use among older adults from a cannabis dispensary in New York State.Cannabis Cannabinoid Res.202272224230
     [Google Scholar]
  39. CuttlerC. MischleyL.K. SextonM. Sex differences in cannabis use and effects: A cross-sectional survey of cannabis users.Cannabis Cannabinoid Res.20161116617510.1089/can.2016.0010 28861492
     [Google Scholar]
  40. CalakosK.C. BhattS. FosterD.W. CosgroveK.P. Mechanisms underlying sex differences in cannabis use.Curr. Addict. Rep.20174443945310.1007/s40429‑017‑0174‑7 29503790
     [Google Scholar]
  41. The Health Effects of Cannabis and CannabinoidsThe Current State of Evidence and Recommendations for Research. Washington (DC).National Academies Press (US)2017
     [Google Scholar]
  42. NavarreteF. García-GutiérrezM.S. GasparyanA. Austrich-OlivaresA. FemeníaT. ManzanaresJ. Cannabis use in pregnant and breastfeeding women: Behavioral and neurobiological consequences.Front. Psychiatry20201158644710.3389/fpsyt.2020.586447 33240134
     [Google Scholar]
  43. ScarboroughB.M. SmithC.B. Optimal pain management for patients with cancer in the modern era.CA Cancer J. Clin.201868318219610.3322/caac.21453 29603142
     [Google Scholar]
  44. LewisM. FloodJ. The transition of cannabis into the mainstream of Australian healthcare: Framings in professional medical publications.J. Cannabis Res.20213116
     [Google Scholar]
  45. ArguetaD.A. AichA. MuqolliF. Considerations for cannabis use to treat pain in sickle cell disease.J. Clin. Med.2020912390210.3390/jcm9123902 33271850
     [Google Scholar]
  46. BoscarinoJ.A. WitheyC.A. DuganR.J. HuY. AucielloJ. AlfieriT. Opioid medication use among chronic non-cancer pain patients assessed with a modified drug effects questionnaire and the association with opioid use disorder.J. Pain Res.2020132697270510.2147/JPR.S275397 33122939
     [Google Scholar]
  47. RudichZ. StinsonJ. JeavonsM. BrownS.C. Treatment of chronic intractable neuropathic pain with dronabinol: Case report of two adolescents.Pain Res. Manag.20038422122410.1155/2003/675976 14679417
     [Google Scholar]
  48. ElhassanMMA MohammedAAA OmerAA AzeemAAM MohammedHMA IbrahimIEM Adverse events of opioids for cancerrelated pain in a resource-limited setting: A cross-sectional study from Sudan.ecancermedicalscience2022161366
     [Google Scholar]
  49. MengH. DaiT. HanlonJ.G. DownarJ. AlibhaiS.M.H. ClarkeH. Cannabis and cannabinoids in cancer pain management.Curr. Opin. Support. Palliat. Care2020142879310.1097/SPC.0000000000000493 32332209
     [Google Scholar]
  50. MaurerM. HennV. DittrichA. HofmannA. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.Eur. Arch. Psychiatry Neurol. Sci.199024011410.1007/BF02190083 2175265
     [Google Scholar]
  51. Pain Management and the Opioid EpidemicBalancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington (DC).National Academies Press (US)2017
     [Google Scholar]
  52. VučkovićS. SrebroD. VujovićK.S. VučetićČ. ProstranM. Cannabinoids and pain: New insights from old molecules.Front. Pharmacol.20189125910.3389/fphar.2018.01259 30542280
     [Google Scholar]
  53. CarcieriC. TomaselloC. SimieleM. Cannabinoids concentration variability in cannabis olive oil galenic preparations.J. Pharm. Pharmacol.201770114314910.1111/jphp.12845 29057480
     [Google Scholar]
  54. AviramJ Samuelly-LeichtagG Efficacy of cannabis-based medicines for pain management: A systematic review and metaanalysis of randomized controlled trials.Pain Physician2017620;6E7559610.36076/ppj.20.5.E755 28934780
     [Google Scholar]
  55. Bar-Lev SchleiderL. MechoulamR. LedermanV. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer.Eur. J. Intern. Med.201849374310.1016/j.ejim.2018.01.023 29482741
     [Google Scholar]
  56. DowellD. CDC Clinical practice guideline for prescribing opioids for pain - United States, 2022.MMWR Recomm. Rep.2022713195
     [Google Scholar]
  57. BolshakovaM. BluthenthalR. SussmanS. Opioid use and misuse: Health impact, prevalence, correlates and interventions.Psychol. Health20193491105113910.1080/08870446.2019.1622013 31177850
     [Google Scholar]
  58. KhalidN. PatelP. SinghA. Cannabis versus opioids for pain.In: StatPearls.Treasure Island, (FL)StatPearls Publishing2024
     [Google Scholar]
  59. FordjourE. ManfulC.F. SeyA.A. Cannabis: A multifaceted plant with endless potentials.Front. Pharmacol.202314120026910.3389/fphar.2023.1200269 37397476
     [Google Scholar]
  60. CooperZ.D. AbramsD.I. GustS. SalicrupA. ThrockmortonD.C. Challenges for clinical cannabis and cannabinoid research in the United States.J. Natl. Cancer Inst. Monogr.202120215811412210.1093/jncimonographs/lgab009 34850896
     [Google Scholar]
  61. PacificiR. MarcheiE. SalvatoreF. GuandaliniL. BusardòF.P. PichiniS. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry.Clinical Chemistry and Laboratory Medicine (CCLM)201755101555156310.1515/cclm‑2016‑1060 28207408
     [Google Scholar]
  62. Pourseyed LazarjaniM. TorresS. HookerT. FowlieC. YoungO. SeyfoddinA. Methods for quantification of cannabinoids: A narrative review.J. Cannabis Res.2020213510.1186/s42238‑020‑00040‑2 33526084
     [Google Scholar]
  63. SchlagA.K. HindochaC. ZafarR. NuttD.J. CurranH.V. Cannabis based medicines and cannabis dependence: A critical review of issues and evidence.J. Psychopharmacol.2021357773785
     [Google Scholar]
  64. WHO review of cannabis and cannabis-related substances.Available from: https://www.who.int/teams/health-product-and-policy-standards/controlled-substances/who-review-of-cannabis-and-cannabis-related-substances
  65. de SouzaM.R. HenriquesA.T. LimbergerR.P. Medical cannabis regulation: An overview of models around the world with emphasis on the Brazilian scenario.J. Cannabis Res.2022413310.1186/s42238‑022‑00142‑z 35710586
     [Google Scholar]
  66. LegareC.A. Raup-KonsavageW.M. VranaK.E. Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals.Pharmacology20221073-413114910.1159/000521683 35093949
     [Google Scholar]
  67. SinghK. BhushanB. ChanchalD.K. Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: A comprehensive review.Behav. Neurol.2023202311710.1155/2023/8825358 37868743
     [Google Scholar]
  68. ConnorJ.P. StjepanovićD. Le FollB. HochE. BudneyA.J. HallW.D. Cannabis use and cannabis use disorder.Nat. Rev. Dis. Primers2021711610.1038/s41572‑021‑00247‑4 33627670
     [Google Scholar]
  69. KluweL. ScholzeC. SchmidbergL.M. Medical cannabis alleviates chronic neuropathic pain effectively and sustainably without severe adverse effect: A retrospective study on 99 cases.Med. Cannabis Cannabinoids202361899610.1159/000531667 37900896
     [Google Scholar]
  70. MarcuJ. The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: A brief reportDialogues Clin. Neurosci.202022328929310.31887/DCNS.2020.22.3/jmarcu 33162772
     [Google Scholar]
  71. SevignyE.L. GreathouseJ. MedhinD.N. Health, safety, and socioeconomic impacts of cannabis liberalization laws: An evidence and gap map.Campbell Syst. Rev.2023194e136210.1002/cl2.1362 37915420
     [Google Scholar]
  72. Cannabis policy: Status and recent developmentsAvailable from: www.euda.europa.euhttps://www.euda.europa.eu/publications/topic-overviews/cannabis-policy/html_en
  73. SchillingJ.M. HughesC.G. WallaceM.S. SextonM. BackonjaM. Moeller-BertramT. Cannabidiol as a treatment for chronic pain: A survey of patients’ perspectives and attitudes.J. Pain Res.2021141241125010.2147/JPR.S278718 33981161
     [Google Scholar]
  74. BradfordA.C. BradfordW.D. Medical marijuana laws reduce prescription medication use in medicare part D.Health Aff.20163571230123610.1377/hlthaff.2015.1661 27385238
     [Google Scholar]
  75. SohlerN.L. StarrelsJ.L. KhalidL. Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain.Subst. Use Misuse201853101602160710.1080/10826084.2017.1416408 29338578
     [Google Scholar]
  76. BilbaoA. SpanagelR. Medical cannabinoids: A pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC Med.202220125910.1186/s12916‑022‑02459‑1 35982439
     [Google Scholar]
  77. GonçalvesJ. RosadoT. SoaresS. Cannabis and its secondary metabolites: Their use as therapeutic drugs, toxicological aspects, and analytical determination.Medicines2019613110.3390/medicines6010031 30813390
     [Google Scholar]
  78. WolfeD. CoraceK. ButlerC. Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature.PLoS One2023182e028182610.1371/journal.pone.0281826 36800328
     [Google Scholar]
  79. CanadaH. For health care professionals: Cannabis and cannabinoids.2018Available from: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html
/content/journals/cdth/10.2174/0115748855319068240915174752
Loading
Therapeutic Efficacy of Cannabis in the Management of Chronic Pain: An Opinion Paper
Curr Drug Ther 20, 920 (2025); https://doi.org/10.2174/0115748855319068240915174752
/content/journals/cdth/10.2174/0115748855319068240915174752
/content/journals/cdth/10.2174/0115748855319068240915174752
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Cannabis; CBD; drugs; efficacy; pain management; safety; THC

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test